U.S. markets close in 3 hours 12 minutes

ERYTECH Pharma S.A. (ERYP.PA)

Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
4.2850-0.0150 (-0.35%)
At close: 5:35PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.3000
Open4.3200
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range4.2550 - 4.3500
52 Week Range4.1650 - 10.4400
Volume133,231
Avg. Volume124,907
Market Cap111.606M
Beta (5Y Monthly)1.87
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    All
    News
    • Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2021
      GlobeNewswire

      Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2021

      Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2021. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net (2)

    • ERYTECH to Participate in Upcoming Virtual Investor Conferences in June
      GlobeNewswire

      ERYTECH to Participate in Upcoming Virtual Investor Conferences in June

      ERYTECH to Participate in Upcoming Virtual Investor Conferences in June Lyon (France) and Cambridge, MA (U.S.), May 26, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced its partipation in the following investor conferences in the month of June. Jefferies Virtual Healthcare Conference – June 1- 4, 2021 Gil Beyen, Chief Executive Officer, will be participating in a fireside chat followed by a virtual Q&A session on Friday June 4th at 10am (ET). WEBCAST LINK A replay of the session will be on the Jefferies conference website, as well as on ERYTECH’s website, under the “Investors” section at investors.erytech.com, for 30-days following the conference. For more information please visit the Conferences & Events section of the Jefferies website. JMP Securities Life Sciences Conference – June 16 & 17, 2021 Gil Beyen, Chief Executive Officer, will present a company overview followed by a virtual Q&A session on Wednesday June 16th at 2pm (ET). WEBCAST LINK A link to the live audio webcast as well as the replay of the webcast will be available on ERYTECH’s website, under the “Investors” section at investors.erytech.com. For more information about the JMP Securities Life Sciences Conference, please refer to the JMP conference website Spring European Midcap Event – June 24 & 25, 2021 Gil Beyen, Chief Executive Officer and Eric Soyer Chief Financial Offier will participate in one-on-one meetings on Thursday June 24th. For more information about the Spring European Midcap Event, please refer to the CF&B conference website If you are interested in arranging a one-on-one meeting, please contact your conference representative. About ERYTECH and eryaspase ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial in acute lymphoblastic leukemia recently reported positive results, and a Phase 1 IST in 1L advanced pancreatic cancer is ongoing. Eryaspase received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced pancreatic cancer. The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of pancreatic cancer and ALL. ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine. ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit www.erytech.com CONTACTS ERYTECH Eric SoyerCFO & COOLifeSci Advisors, LLCInvestor RelationsCorey Davis, Ph.D.NewCapMathilde Bohin / Louis-Victor DelouvrierInvestor relationsNicolas MerigeauMedia relations+33 4 78 74 44 38investors@erytech.com+1 (212) 915 2577 cdavis@lifesciadvisors.com+33 1 44 71 94 94 erytech@newcap.eu Attachment ERYTECH_PR_2021_ June Conference_curtain raiser_EN_vf

    • Erytech’s Combined Shareholders’ Meeting on June 25, 2021
      GlobeNewswire

      Erytech’s Combined Shareholders’ Meeting on June 25, 2021

      ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 25, 2021Live webcast of the Shareholders’ Meeting Availability of the preparatory documents for the Shareholders’ Meeting SS RELEASE Lyon (France), May 25, 2020 – Erytech Pharma (Euronext Paris and Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, is announcing that its Combined Shareholders’ Meeting will be held in French in closed session at 2pm CEST on Friday, June 25, 2021, and also the associated details. In compliance with recent French legislation1 and per the recommendations of the French financial markets authority (Autorité des Marchés Financiers or AMF), Erytech confirms that its Annual Ordinary and Extraordinary Shareholders Meeting will take place at 2pm (Paris time) on June 25, 2021 in a closed session, without any shareholders being present in person. Please note that the AMF strongly encourages shareholders to vote, as such right is a fundamental prerogative of each shareholder, by means of distance voting, with all votes to be cast ahead of the Shareholders’ Meeting. Voting procedures For your vote to count: I. Voting or giving proxy by mail with the paper form For holders of registered shares: registered shareholders must return their completed and signed postal voting form or proxy form, using the T envelope provided with the notice of meeting, to Société Générale Securities Services, Service des Assemblées, CS 30812, 44308 Nantes Cedex 03, FRANCE. For holders of bearer shares: holders of bearer shares must return their single postal voting form or proxy form, completed and signed, to the authorized financial intermediary who manages their securities account. The financial intermediary will prove that they are shareholders and will return the form to Société Générale Securities Services. These documents must reach us by June 22, 2021. In the event that a proxy is given to a natural or legal person, the proxy holder shall send its voting instruction to Société Générale, by e-mail to the following address: assemblees.generales@sgss.socgen.com. The deadline for receipt is June 21, 2021. II. Voting or giving proxy by internetThe VOTACCESS secure platform will be open from 9:00 a.m. on June 7, 2021 until 3:00 p.m., Paris time, on June 24, 2021. However, in order to avoid any possible saturation of the VOTACCESS site, shareholders are advised not to wait until the day before the meeting to vote. Shareholders’ Meeting to be held in closed session without any shareholders being present in person All the requisite arrangements for the Shareholders’ Meeting to proceed smoothly amid the current health situation have been made: shareholders will be able to follow events at the Shareholders’ Meeting live in a webconference. The registration link for this event will be available on the company's website soon.for written questions, because it will not be possible for shareholders to ask questions during the Shareholders’ Meeting, Erytech recommends that they should send in written questions to the registered office by registered letter with return receipt requested to the Chairman of the Board of Directors or by email to legal@erytech.com no later than two business days prior to the Shareholders’ Meeting (i.e., by June 23, 2021). Given the exceptional circumstances, the Company is asking shareholders to email in their questions, wherever possible, attaching a certificate proving that they own shares in Erytech. Availability of the documents for the Shareholders’ Meeting The notice of meeting including the agenda and the draft resolutions, together with the principal details for attending and voting at the Combined Shareholders’ Meeting was published in the French Bulletin of Legal Announcements no. 60 on May 19, 2021. Shareholders have access to the preparatory and information documents for the Shareholders’ Meeting as provided for by law and the regulations. They may also be viewed on the Company website at: https://investors.erytech.com/general-meeting About ERYTECH and eryaspase ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial in acute lymphoblastic leukemia recently reported positive results, and a Phase 1 IST in 1L advanced pancreatic cancer is ongoing. Eryaspase received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced pancreatic cancer. The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of pancreatic cancer and ALL. ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine. ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. For more information, please visit www.erytech.com CONTACTS ERYTECH Eric SoyerCFO & COOLifeSci Advisors, LLCInvestor RelationsCorey Davis, Ph.D.NewCapMathilde Bohin / Louis-Victor DelouvrierInvestor relationsNicolas MerigeauMedia relations+33 4 78 74 44 38investors@ERYTECH.com+1 (212) 915 - 2577 cdavis@lifesciadvisors.com+33 1 44 71 94 94 ERYTECH@newcap.eu 1 Law of 23 March 2020 to respond to COVID-19 and decree No. 2020-321 dated 25 March 2020 as amended and extended by decree No. 2020-1497 dated December 2, 2020 and by decree No. 2021-255 dated March 9, 2021 Attachment ERYTECH_PR_AG2021_EN_vf-2